Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$110.12 -2.0%	$106.39	$72.21 ▼ $139.13	$5.53B	0.46	665,438 shs	595,554 shs
CORT Corcept Therapeutics	$71.41 -1.9%	$72.66	$32.33 ▼ $117.33	$7.72B	0.15	1.18 million shs	1.05 million shs
JAZZ Jazz Pharmaceuticals	$112.30 +0.8%	$108.20	$95.49 ▼ $148.06	$6.74B	0.32	826,555 shs	632,242 shs
RPRX Royalty Pharma	$36.51 +0.7%	$34.34	$24.05 ▼ $36.69	$20.38B	0.5	3.71 million shs	2.82 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.97%	+1.58%	+5.78%	+5.41%	+33.00%
CORT Corcept Therapeutics	-1.87%	+4.77%	+1.93%	+10.54%	+120.74%
JAZZ Jazz Pharmaceuticals	+0.77%	+2.90%	+3.50%	+10.59%	+8.68%
RPRX Royalty Pharma	+0.75%	+2.82%	+4.79%	+13.42%	+37.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6918 of 5 stars	4.5	1.0	0.0	4.5	2.2	4.2	0.6
CORT Corcept Therapeutics	4.7715 of 5 stars	3.5	3.0	0.0	4.3	2.1	4.2	1.9
JAZZ Jazz Pharmaceuticals	4.8019 of 5 stars	4.5	1.0	0.0	4.0	1.4	3.3	2.5
RPRX Royalty Pharma	4.9692 of 5 stars	3.6	4.0	3.3	3.7	3.6	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	56.50% Upside
CORT Corcept Therapeutics	3.00	Buy	$138.25	93.60% Upside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$181.71	61.81% Upside
RPRX Royalty Pharma	3.25	Buy	$48.33	32.38% Upside

Current Analyst Ratings Breakdown

Latest JAZZ, AXSM, RPRX, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00
7/10/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$51.00 ➝ $54.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$432.16M	12.55	N/A	N/A	$1.18 per share	93.32
CORT Corcept Therapeutics	$685.45M	11.05	$1.22 per share	58.59	$6.49 per share	11.00
JAZZ Jazz Pharmaceuticals	$4.07B	1.67	$30.60 per share	3.67	$67.72 per share	1.66
RPRX Royalty Pharma	$2.26B	9.07	$4.23 per share	8.64	$17.56 per share	2.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.05	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
CORT Corcept Therapeutics	$141.21M	$1.16	61.56	38.60	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	14.97	6.00	4.81	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.85	19.74	7.51	2.41	48.23%	24.71%	13.87%	8/6/2025 (Estimated)

Latest JAZZ, AXSM, RPRX, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
8/4/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	N/A	N/A	N/A	$1.05 billion	N/A
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.41%	N/A	47.57%	5 Years

Latest JAZZ, AXSM, RPRX, and CORT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
CORT Corcept Therapeutics	N/A	3.07	2.96
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
RPRX Royalty Pharma	0.68	1.56	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
CORT Corcept Therapeutics	20.50%
JAZZ Jazz Pharmaceuticals	4.30%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
CORT Corcept Therapeutics	300	106.05 million	84.31 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable

JAZZ, AXSM, RPRX, and CORT Headlines

Recent News About These Companies

Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - Still a Buy?

1 hour ago | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Purchased by Bryn Mawr Capital Management LLC

July 15 at 9:33 AM | marketbeat.com

12,430 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Purchased by Strata Wealth Advisors LLC

July 14 at 8:58 AM | marketbeat.com

Bank of New York Mellon Corp Has $45.53 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX)

July 14 at 3:59 AM | marketbeat.com

Rehmann Capital Advisory Group Makes New $549,000 Investment in Royalty Pharma PLC (NASDAQ:RPRX)

July 11, 2025 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Should You Buy?

July 10, 2025 | marketbeat.com

D.A. Davidson & CO. Sells 10,511 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

July 9, 2025 | marketbeat.com

Teacher Retirement System of Texas Cuts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

July 9, 2025 | marketbeat.com

NASDAQ:RPRX Financials | Royalty Pharma Plc - Investing.com

July 8, 2025 | investing.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by China Universal Asset Management Co. Ltd.

July 8, 2025 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Bought by Sumitomo Mitsui DS Asset Management Company Ltd

July 6, 2025 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Bought by KBC Group NV

July 4, 2025 | marketbeat.com

Sumitomo Mitsui Trust Group Inc. Sells 88,416 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

July 3, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Purchases 21,729 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

July 3, 2025 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

July 3, 2025 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Stake Reduced by New South Capital Management Inc.

July 2, 2025 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - Here's Why

July 1, 2025 | marketbeat.com

Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline

July 1, 2025 | seekingalpha.com

Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year

June 29, 2025 | finance.yahoo.com

Royalty Pharma PLC (NASDAQ:RPRX) Holdings Raised by Robeco Institutional Asset Management B.V.

June 29, 2025 | marketbeat.com

Asset Management One Co. Ltd. Acquires 12,148 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

June 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ, AXSM, RPRX, and CORT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$110.12 -2.21 (-1.97%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$110.10 -0.03 (-0.02%)

As of 07/15/2025 07:58 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$71.41 -1.36 (-1.87%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$75.00 +3.59 (+5.03%)

As of 04:02 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$112.30 +0.86 (+0.77%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$112.26 -0.03 (-0.03%)

As of 07/15/2025 07:49 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$36.51 +0.27 (+0.75%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$36.40 -0.11 (-0.31%)

As of 07/15/2025 07:51 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time